Elan Shares Climb on $3.25B Biogen's Tysabri Deal

Feb. 6 (Bloomberg) -- Bloomberg's Caroline Hyde reports on what is next for Elan Corp. as Biogen Idec Inc. agreed to acquire the company's stake in the multiple sclerosis drug Tysabri for $3.25 billion in cash plus future royalties. She speaks on Bloomberg Television's "The Pulse."
Does Apple TV Need a Revamp?
34:17 - Homebrew VC Partner Hunter Walk, Technalysis Founder Bob O’Donnell and IDC Chief Research Officer Crawford Del Prete discuss Apple to unveil a new TV box this fall and the future of Apple’s streaming service. They speak with Bloomberg’s Emily Chang on “Bloomberg West.” (Source: Bloomberg)
  • Why Would Microsoft Invest in Uber?
  • Why U.S. Wage Growth Has Screeched to a Halt
  • The China Slowdown Felt Around the World